GANX Gain Therapeutics Inc
Price (delayed)
$1.85
Market cap
$51.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
$41.67M
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new
Highlights
The EPS has grown by 48% YoY and by 19% from the previous quarter
Gain Therapeutics's debt has decreased by 36% YoY and by 15% QoQ
GANX's revenue has plunged by 100% YoY
Gain Therapeutics's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of GANX
Market
Valuations
Earnings
Shares outstanding
27.79M
Market cap
$51.41M
Enterprise value
$41.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$20.35M
Net income
-$20.41M
EBIT
-$19.87M
EBITDA
-$19.79M
Free cash flow
-$18.9M
Per share
Balance sheet
Liquidity
EPS
-$0.89
EPS diluted
-$0.89
Free cash flow per share
-$0.83
Book value per share
$0.28
Revenue per share
$0
TBVPS
$0.52
Total assets
$12.12M
Total liabilities
$4.78M
Debt
$653,015
Equity
$7.34M
Working capital
$7.69M
Debt to equity
0.09
Current ratio
2.97
Quick ratio
2.66
Net debt/EBITDA
0.49
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-135.5%
Return on equity
-222.6%
Return on invested capital
N/A
Return on capital employed
-242%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GANX stock price
How has the Gain Therapeutics stock price performed over time
Intraday
0%
1 week
6.32%
1 month
-20.94%
1 year
-45.43%
YTD
-14.35%
QTD
-3.14%
Financial performance
How have Gain Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.35M
Net income
-$20.41M
Gross margin
N/A
Net margin
N/A
GANX's revenue has plunged by 100% YoY
Gain Therapeutics's gross profit has shrunk by 100% YoY
GANX's operating income is up by 9% YoY and by 5% QoQ
The net income is up by 8% year-on-year and by 4.5% since the previous quarter
Growth
What is Gain Therapeutics's growth rate over time
Valuation
What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
6.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 48% YoY and by 19% from the previous quarter
The stock's price to book (P/B) is 86% more than its 5-year quarterly average of 3.6 and 22% more than its last 4 quarters average of 5.5
GANX's equity is down by 42% year-on-year and by 18% since the previous quarter
GANX's revenue has plunged by 100% YoY
Efficiency
How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has decreased by 15% YoY and by 9% QoQ
GANX's return on assets is down by 10% year-on-year and by 6% since the previous quarter
Dividends
What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GANX.
Financial health
How did Gain Therapeutics financials performed over time
GANX's total assets is 153% greater than its total liabilities
GANX's total assets is down by 35% year-on-year and by 16% since the previous quarter
GANX's quick ratio is down by 22% YoY
Gain Therapeutics's debt is 91% lower than its equity
GANX's equity is down by 42% year-on-year and by 18% since the previous quarter
Gain Therapeutics's debt has decreased by 36% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.